CTLA4 and neoplasm: RCT001 in synergy with anti-PD-1 and anti-CTLA4 yielded a substantial increase of M1 TAMs (Fig. 5d), a decreased of TANs (Tumor Associated Neutrophils) and mature TANs (associated with poor prognosis in RCC, Fig. 5f), accompanied by an increase in activated dendritic cells (DCs, Fig. 5g) and activated natural killer (NKs, Fig. 5h).